Company profile
SPERO THERAPEUTICS, INC.
NASDAQ:SPROBiotechnology: Pharmaceutical Preparations
Drug pipeline (3)
| Asset | Stage | Revenue | Trials | Status |
|---|---|---|---|---|
| TEBIPENEM PIVOXIL HYDROBROMIDE | phase3 | — | 8 | no active trials |
| SPR-741 | phase1 | — | 2 | no active trials |
| UPLEGANAN | phase1 | — | 3 | no active trials |
Revenue is the latest quarter the company reported for that product, from SEC filings; a fourth quarter is the year less nine months when no filing states one. Trial counts are of the product's ingredients, deduplicated by trial, so products sharing an ingredient share trials.
Clinical trials (22)
| NCT ID | Phase | Status | Start | Completion | Sponsor name | Title |
|---|---|---|---|---|---|---|
| NCT03792308 | phase1 | completed | 2018-12-18 | 2019-12-23 | Spero Therapeutics | A First in Human Study of the Safety and Tolerability of Single and Multiple Doses of SPR206 in Healthy Volunteers |
| NCT03022175 | phase1 | completed | 2016-12-01 | 2017-07-01 | Spero Therapeutics | A First in Human Study of the Safety and Tolerability of Single and Multiple Doses of SPR741 in Healthy Volunteers |
| NCT04238195 | phase1 | completed | 2020-01-19 | 2020-02-26 | Spero Therapeutics | A Single-Dose, Randomized, Placebo- and Active-Control, Four-Way, Cross-Over Study for the Evaluation of the Effect of Tebipenem Pivoxil Hydrobromide (TBPM-PI-HBr) on the QT/QTc Intervals in Adult Healthy Subjects |
| NCT06059846 | phase3 | completed | 2023-12-21 | 2025-01-27 | Spero Therapeutics | A Study of Oral Tebipenem Pivoxil Hydrobromide (TBP-PI-HBr) Compared to Intravenous Imipenem-cilastatin in Participants With Complicated Urinary Tract Infection (cUTI) or Acute Pyelonephritis (AP) |
| NCT03796910 | phase1 | completed | 2018-12-18 | 2019-09-24 | Spero Therapeutics | A Study of the Safety, Tolerability, and Pharmacokinetics of SPR720 in Healthy Volunteers |
FDA applications (0)
No records yet.